|Reactivity||Human, Mouse, Horse, Bovine, Dog|
|Dilution||IHC-P (4 µg/ml)|
|Other Names||Lysophosphatidic acid receptor 3, LPA receptor 3, LPA-3, Lysophosphatidic acid receptor Edg-7, LPAR3, EDG7, LPA3|
|Target/Specificity||Human EDG7. BLAST analysis of the peptide immunogen showed no homology with other human proteins.|
|Reconstitution & Storage||Long term: -70°C; Short term: +4°C|
|Precautions||LPAR3 / LPA3 / EDG7 Antibody (Cytoplasmic Domain) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins.|
|Cellular Location||Cell membrane; Multi-pass membrane protein.|
|Tissue Location||Most abundantly expressed in prostate, testes, pancreas, and heart, with moderate levels in lung and ovary. No detectable expression in brain, placenta, liver, skeletal muscle, kidney, spleen, thymus, small intestine, colon, or peripheral blood leukocytes|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins.
Bandoh K.,et al.J. Biol. Chem. 274:27776-27785(1999).
Im D.-S.,et al.Mol. Pharmacol. 57:753-759(2000).
Kopatz S.A.,et al.Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
Contos J.J.A.,et al.Mol. Pharmacol. 58:1188-1196(2000).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.